Use of mutational pattern in 5′-NCR and VP1 regions of polioviruses for molecular diagnosis

Molecular and Cellular Probes

Volumn 21, Issue 4, 2007, Pages 267-275

  Pliaka, V ^a   Dedepsidis, E ^a   Kyriakopoulou, Z ^a   Papadopoulou, I ^a   Levidiotou, S ^b   Markoulatos, P ^a  

^a School of Health Sciences   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

5 NCR; Molecular diagnosis; Mutations; Polioviruses; Sequencing; VP1

Indexed keywords

ARTICLE; BIOINFORMATICS; DIAGNOSTIC PROCEDURE; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENOMICS; NONHUMAN; NUCLEOTIDE SEQUENCE; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AMINO ACID SEQUENCE; BASE SEQUENCE; CAPSID; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; GENOTYPE; HUMANS; INFANT; MOLECULAR SEQUENCE DATA; MUTAGENESIS; MUTATION; NUCLEIC ACID CONFORMATION; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SEQUENCE ANALYSIS, DNA;

ENTEROVIRUS; PICORNAVIRIDAE; POLIOVIRUS;

EID: 34248180086     PISSN: 08908508     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcp.2007.01.004     Document Type: Article

References (41)

1. Wimmer E., Hellen C.U., and Cao X. Genetics of poliovirus. Ann Rev Genet 27 (1993) 353-436
2. Emini E.A., Jameson B.A., Lewis A.J., Larsen G.R., and Wimmer E. Poliovirus neutralization epitopes: analysis and localization with neutralizing monoclonal antibodies. J Virol 43 (1982) 997-1005
3. Hogle J.M., Chow M., and Filman D.J. Three-dimensional structure of poliovirus at 2.9 A resolution. Science 229 4720 (1985) 1358-1365
4. Minor P.D., Ferguson M., Evans D.M.A., Almond J.W., and Icenogle J.P. Antigenic structure of polioviruses of serotypes 1, 2 and 3. J Gen Virol 67 pt 7 (1986) 1283-1291
5. Bernhardt G., Harber J., Zibert A., deCrombrugghe M., and Wimmer E. The poliovirus receptor: identification of domains and amino acid residues critical for virus binding. Virology 203 2 (1994) 344-356
6. Colston E., and Racaniello V.R. Soluble receptor-resistant poliovirus mutants identify surface and internal capsid residues that control interaction with the cell receptor. EMBO J 13 24 (1994) 5855-5862
7. Harber J., Bernhardt G., Lu H.H., Sgro J.Y., and Wimmer E. Canyon rim residues, including antigenic determinants, modulate serotype-specific binding of polioviruses to mutants of the poliovirus receptor. Virology 214 2 (1995) 559-570
8. Liao S., and Racaniello V.R. Allele-specific adaptation of poliovirus VP1 B-C loop variants to mutant cell receptors. J Virol 71 12 (1997) 9770-9777
9. Filman D.J., Syed R., Chow M., Macadam A.J., and Hogle J.M. Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. EMBO J 8 5 (1989) 1567-1579
10. Andino R., Rieckhof G.E., and Baltimore D. A functional ribonucleoprotein complex forms around the 5′ end of poliovirus RNA. Cell 63 (1990) 369-380
11. Rohll J.B., Percy N., Ley R., Evans D.J., Almond J.W., and Barclay W.S. The 5′-untranslated regions of picornavirus RNAs contain independent functional domains essential for RNA replication and translation. J Virol 68 (1994) 4384-4391
12. Friedrich F. Genomic modifications in Sabin vaccine strains isolated from vaccination-associated cases, healthy contacts and healthy vaccinee. Acta Virol 40 (1996) 157-170
13. Bouchard M.J., Lam D.H., and Racaniello V.R. Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. J Virol 69 8 (1995) 4972-4978
14. Macadam A.J., Pollard S.R., Ferguson G., Skuce R., Wood D., and Almond J.W. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 192 (1993) 18-26
15. Macadam A.J., Arnold C., Howlett J., John A., Marsden S., Taffs F., et al. Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccines. Virology 172 (1989) 408-414
16. Friedrich F. Neurologic complications associated with oral poliovirus vaccine and genomic variability of the vaccine strains after multiplication in humans. Acta Virol 42 (1998) 187-194
17. World Health Organization. Manual for the virological investigation of poliomyelitis (2004), World Health Organization, Geneva, Switzerland
18. Casas I., Powell L., Klapper P.E., and Cleator G.M. New method for the extraction of viral RNA and DNA from cerebrospinal fluid for use in the polymerase chain reaction assay. J Virol Meth 53 (1995) 25-36
19. Balanant J., Guillot S., Candrea A., Delpeyroux F., and Crainic R. The natural genomic variability of poliovirus analyzed by a restriction fragment length polymorphism assay. Virology 184 (1991) 645-654
20. Oberste M.S., Maher K., Flemister M.R., Marchetti G., Kilpatrick D.R., and Pallansch M.A. J Clin Microbiol 38 (2000) 1170-1174
21. Georgopoulou A., Markoulatos P., Spyrou N., and Vamvakopoulos N.C. Improved genotyping vaccine and wild-type poliovirus strains by restriction fragment length polymorphism analysis: clinical diagnostic implications. J Clin Microbiol 38 (2000) 4337-4342
22. Wien M.W., Curry S., Filman D.J., and Hogle J.M. Structural studies of poliovirus mutants that overcome receptor defects. Nat Struct Biol 4 (1997) 666-674
23. Cherkasova E.A., Korotkova E.A., Yakovenko M.L., Ivanova O.E., Eremeeva T.P., Cumakov K.M., et al. Long-term circulation of vaccine-derived poliovirus that causes paralytic disease. J Virol 76 (2002) 6791-6799
24. Figlerowicz M., Alejska M., Kurzynska-Kokorniak A., and Figlerowicz M. Genetic variability: the key problem in the prevention and therapy of RNA-based virus infections. Med Res Rev 23 (2003) 488-518
25. Αgol V.I. Genome instability in picornaviruses. Mol Biol 36 (2002) 216-222
26. Equestre M., Genovese D., Cavalieri F., Fiore L., Santoro R., and Bercoff R.P. Identification of a consistent pattern of mutations in neurovirulent variants derived from the Sabin vaccine strain of poliovirus type 2. J Virol 65 (1991) 2707-2710
27. Christodoulou C., Colbere-Garapin F., Macadam A., Taffs L.F., Marsden S., Minor P., et al. Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. J Virol 64 (1990) 4922-4929
28. Kawamura N., Kohara M., Abe S., Komatsu T., Tago K., Arita M., et al. Determinants in the 5′ noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J Virol 63 (1989) 1302-1309
29. Herremans T., Reimerink J.H., Kimman T.G., van der Avoort H.G., and Koopmans M.P. Antibody responses to antigenic sites 1 and 3 of serotype 3 poliovirus after vaccination with oral live attenuated or inactivated poliovirus vaccine and after natural exposure. Clin Diagn Lab Immunol 7 (2000) 40-44
30. Ochs K., Zeller A., Saleh L., Bassili G., Song Y., Sonntag A., et al. Impaired binding of standard initiation factors mediates poliovirus translation attenuation. J Virol 77 (2003) 115-122
31. Minor P.D. Poliovirus vaccination: current understanding of poliovirus interactions in humans and implications for the eradication of poliomyelitis. Expert reviews in molecular medicine (1999), Cambridge University Press, Cambridge
32. Muzychenko A.R., Lipskaya G., Maslova S.V., Svitkin Y.V., Pilipenko E.V., Nottay B.K., et al. Coupled mutations in the 5′-untranslated region of the Sabin poliovirus strains during in vivo passages: structural and functional implications. Virus Res 21 (1991) 111-122
33. Macadam A.J., Pollard S.R., Ferguson G., Dunn G., Skuce R., Almond J.W., et al. The 5′ noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. Virology 181 (1991) 451-458
34. Bellmunt A., May G., Zell R., Pring-Akerblom P., Verhagen W., and Heim A. Evolution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient. Virology 265 (1999) 178-184
35. Georgescu M.M., Balanant J., Macadam A., Otelea D., Combiescu M., Combiescu A.A., et al. Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. J Virol 71 (1997) 7758-7768
36. Kew O.M., Sutter R.W., Nottay B.K., McDonugh M.J., Prevots D.R., Quick L., et al. Prolonged replication of a Type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol 36 (1998) 2893-2899
37. Wiegers K., Uhlig H., and Dernick R. Nag1B of poliovirus type 1: a discontinuous epitope formed by two loops of VP1 comprising residues 96-104 and 141-152. Virology 170 (1989) 583-586
38. Moss E.G., and Racaniello V.R. Host range determinants located on the interior of the poliovirus capsid. EMBO J 10 (1991) 1067-1074
39. Dowdle W.R., De Gourville E., Kew O.M., Pallansch M.A., and Wood D.J. Polio eradication: the OPV paradox. Rev Med Virol 13 (2003) 277-291
40. Blomqvist S., Bruu A.L., Stenvik M., and Hovi T. Characterization of a recombinant type 3/type 2 poliovirus isolated from a healthy vaccinee and containing a chimeric capsid protein VP1. J Gen Virol 84 (2003) 573-580
41. Martin J., Samoilovich E., Dunn G., Lackenby A., Feldman E., Heath A., et al. Isolation of an intertypic poliovirus capsid recombinant from a child with vaccine-associated paralytic poliomyelitis. J Virol 76 (2002) 1092-10928